Lilly Targets Watson Over Osteoporosis Drug ANDA
Eli Lilly & Co. has filed a patent infringement suit against Watson Pharmaceuticals Inc. over the rival drugmaker's plans to market a generic version of postmenopausal osteoporosis treatment Evista....To view the full article, register now.
Already a subscriber? Click here to view full article